Every open market buy and sale of Enliven Therapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $76.4M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when ELVN insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an ELVN officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every ELVN insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | Helen Louise CollinsChief Medical Officer | Sale plan | 5,000 | $46.84 | $234K | 25,000 | Nov 19Form 4 |
| Oct 19, 2026 | Helen Louise CollinsChief Medical Officer | Sale plan | 5,000 | $38.47 | $192K | 25,000 | Oct 21Form 4 |
| Oct 19, 2026 | Benjamin HohlCFO | Sale plan | 6,018 | $38.48 | $232K | 38,000 | Oct 21Form 4 |
| Oct 1, 2026 | J. Scott GarlandDirector | Sale | 13,000 | $46.67 | $607K | 0 | Oct 5Form 4 |
| Sep 17, 2026 | Helen Louise CollinsChief Medical Officer | Sale plan | 5,000 | $50.35 | $252K | 25,000 | Sep 21Form 4 |
| Sep 17, 2026 | Benjamin HohlCFO | Sale plan | 6,018 | $50.35 | $303K | 38,000 | Sep 21Form 4 |
| Aug 17, 2026 | Helen Louise CollinsChief Medical Officer | Sale plan | 5,000 | $58.59 | $293K | 25,000 | Aug 19Form 4 |
| Aug 17, 2026 | Benjamin HohlCFO | Sale plan | 6,018 | $58.58 | $353K | 40,036 | Aug 19Form 4 |
| Aug 4, 2026 | Mika K DerynckDirector | Sale plan | 158,795 | $60.21 | $9.6M | 0 | Aug 6Form 4 |
| Jul 17, 2026 | Helen Louise CollinsChief Medical Officer | Sale plan | 5,000 | $52.67 | $263K | 25,000 | Jul 21Form 4 |
| Jul 17, 2026 | Benjamin HohlCFO | Sale plan | 6,018 | $52.64 | $317K | 46,054 | Jul 21Form 4 |
| Jul 6, 2026 | Lori Anne KunkelDirector | Sale plan | 10,000 | $50.49 | $505K | 41,884 | Jul 8Form 4 |
| Jun 22, 2026 | Orbimed Advisors LLC10% owner | Sale | 860,123 | $45.36 | $39M | 6,555,102 | Jun 24Form 4 |
| Jun 17, 2026 | Helen Louise CollinsChief Medical Officer | Sale plan | 5,000 | $43.80 | $219K | 25,000 | Jun 22Form 4 |
| Jun 17, 2026 | Benjamin HohlCFO | Sale plan | 6,018 | $43.80 | $264K | 51,000 | Jun 22Form 4 |
ELVN insider trading FAQ
Are ELVN insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of ELVN on the open market in 0 trades, and 9 sold $76.4M in 33 trades, 31% of that under pre-arranged trading plans.
When did an ELVN insider last buy shares?
There has been no open market insider purchase of ELVN in the last two years.
When did an ELVN insider last sell shares?
Helen Louise Collins (Chief Medical Officer) sold 5,000 shares for $234K on Nov 17, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
